Product Details

The 5G4.6 monoclonal antibody reacts with the TNF family member TL1A, also known as TNFSF15. TL1A is expressed on activated T cells, dendritic cells, monocytes and endothelial cells. TL1A expression has been shown to be induced by pro-inflammatory stimuli such as TNFα and IL-1α. In contrast to the TNFα receptors, which are expressed on essentially all cells, the receptor for TL1A, DR3 (TNFRSF25), is primarily expressed on T cells, NK cells, and NKT cells, thereby limiting the effects of TL1A. TL1A-DR3 interactions are thought to promote effector T cell proliferation at the site of inflammation and in draining lymph nodes. Blockade of TL1A-DR3 interactions strikingly reduces pathology in several animal models in which autoreactive T cells play a role. TL1A has been linked to inflammatory bowel disease. The 5G4.2 antibody has been shown to block TL1A binding to DR3 and reduce disease severity in mouse models of colitis.

Specifications

Isotype	Armenian hamster IgG
Recommended Isotype Control(s)	InVivoMAb polyclonal Armenian hamster IgG
Recommended Dilution Buffer	InVivoPure pH 7.0 Dilution Buffer
Conjugation	This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Immunogen	Recombinant murine TL1A
Reported Applications	in vivo TL1A neutralization Flow cytometry
Formulation	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin	<2EU/mg (<0.002EU/μg) Determined by LAL gel clotting assay
Purity	>95% Determined by SDS-PAGE
Sterility	0.2 μM filtered
Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A
RRID	AB_2819050
Molecular Weight	150 kDa
Storage	The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

InVivoMAb anti-mouse TL1A (TNFSF15)